# EDGAR Filing Document

**Accession Number:** 0001576280
**File Stem:** 0001193125-23-050767
**Filing Date:** 2023-2
**Character Count:** 11036
**Document Hash:** cac60aa9a5f4d20ed7f823f115176112
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-050767.hdr.sgml**: 20230227

**ACCESSION NUMBER**: 0001193125-23-050767

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230221

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230227

**DATE AS OF CHANGE**: 20230227

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Guardant Health, Inc.
- **CENTRAL INDEX KEY:** 0001576280
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 454139254
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38683
- **FILM NUMBER:** 23674885

**BUSINESS ADDRESS:**
- **STREET 1:** 3100 HANOVER STREET
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** 855-698-8887

**MAIL ADDRESS:**
- **STREET 1:** 3100 HANOVER STREET
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of report (Date of earliest event reported): February 21, 2023

------

## GUARDANT HEALTH, INC.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38683** | **45-4139254** |
| **(State or other jurisdiction**<br> **of incorporation or organization)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

#### 3100 Hanover Street

#### Palo Alto, California 94304

#### (Address of principal executive offices) (Zip Code)

#### 855-698-8887

#### (Registrant's telephone number, include area code)

#### N/A

#### (Former Name or Former Address, if Changed Since Last Report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange<br>on which registered** |
| Common Stock, par value $0.00001 GH | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 21, 2023, the Board of Directors (the "Board") of Guardant Health, Inc. (the "Company") increased the number of directors on the Board to nine and appointed Musa Tariq as a Class I director of the Company, to be effective as of March 6, 2023. Mr. Tariq will serve on the Board for a term expiring at the 2025 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. In connection with his appointment to the Board, Mr. Tariq was appointed to the nominating and corporate governance committee of the Board.

Mr. Tariq currently serves as the Chief Marketing Officer of GoFundMe, Inc., the world's leading fundraising platform, where he is responsible for driving the company's marketing, brand, and communications functions. Prior to joining GoFundMe in January 2021, Mr. Tariq served as the Global Head of Marketing for Airbnb Experiences at Airbnb, Inc. from September 2018 to December 2020, where he drove brand awareness and adoption for that rapidly growing part of Airbnb's business. Prior to Airbnb, he served as the Chief Brand Officer at Ford Motor Company from January 2017 to March 2018, and has also held marketing leadership roles at Apple, Nike and Burberry. Mr. Tariq holds a Bachelor of Science Degree in Geography and Economics from London School of Economics and Political Science.

Mr. Tariq will receive the standard compensation paid by the Company to all of its non-employee directors under the Company's Amended Non-Employee Director Compensation Program (the "<u>Program</u>"). Pursuant to the Program, Mr. Tariq will receive a stock option award and restricted stock unit award, each with a value of $362,500 (collectively, the "<u>Initial Awards</u>"). Each of the Initial Awards will vest with respect to one-fourth (1/4th) of the shares subject thereto on the first anniversary of Mr. Tariq's appointment to the Board, and as to the remaining three-fourths (3/4ths) of the shares subject thereto on each monthly anniversary of Mr. Tariq's appointment to the Board during the three-year period thereafter, subject to continued service through the applicable vesting date.

In accordance with the Company's customary practice, the Company is entering into its standard form of indemnification agreement with Mr. Tariq, which will require the Company to indemnify him against certain liabilities that may arise as result of his status or service as a director. The description of Mr. Tariq's indemnification agreement is qualified in its entirety by the full text of the form of indemnification agreement, which is attached to the Company's Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on September 18, 2018 as Exhibit 10.8.

There are no arrangements or understandings between Mr. Tariq and any other person pursuant to which he was selected as a director, nor are there any transactions in which Mr. Tariq has an interest that would be reportable under Item 404(a) of Regulation S-K.

On February 27, 2023, the Company issued a press release announcing Mr. Tariq's appointment to the Board, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

#### Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press release of Guardant Health, Inc., dated February 27, 2023](d452747dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **GUARDANT HEALTH, INC.** | **GUARDANT HEALTH, INC.** |
| Date: February 27, 2023 |  |  |
|  | By: | /s/ John G. Saia |
|  |  | John G. Saia |
|  |  | Chief Legal Officer and Corporate Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g452747dsp1.jpg)

**PRESS RELEASE** 

**Musa Tariq joins Guardant Health board of directors** 

**PALO ALTO, Calif.**, February 27, 2023 — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world's leading fundraising platform, Tariq is a distinguished marketing executive with experience leading global consumer brands.

"We are very pleased to welcome Musa Tariq to our board of directors," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "Musa brings a wealth of knowledge and expertise in building some of the world's most recognized brands. His insights will be extremely valuable as we continue to build our brand and shape the company's next chapter to empower every individual to stay one step ahead of cancer."

Since joining GoFundMe in January 2021, Tariq has been recognized for his leadership in Forbes' Entrepreneurial CMO List 2022, and in Insider's Most Innovative CMOs of 2022. Before his role with GoFundMe, Tariq was global head of marketing for Airbnb Experiences where he drove brand awareness and adoption of that rapidly growing part of Airbnb's business. Prior to Airbnb, he was chief brand officer at Ford Motor Company and also held marketing leadership roles at Apple, Nike and Burberry.

"I am excited to join the Guardant Health board at such a pivotal time in the company's evolution," said Tariq. "Guardant is a leader in helping patients at all stages of cancer live longer and healthier lives, and now they've developed a simple blood test to find cancer early, when it's most treatable. I look forward to working with the company's leadership team to advance its mission to transform the future of cancer care."

A distinguished counselor to iconic and emerging global brands, Tariq currently serves as an advisor to MasterClass, The British Fashion Council, Felix Capital and several other starts ups. He has a B.S. in Geography and Economics from London School of Economics.

**About Guardant Health** 

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360<sup>®</sup>, Guardant360 CDx, Guardant360 TissueNext<sup>™</sup>, Guardant360 Response<sup>™</sup>, and GuardantINFINITY<sup>™</sup> tests for advanced-stage cancer, and Guardant Reveal<sup>™</sup> for early-stage cancer. The Guardant Health screening portfolio, including the commercially launched Shield<sup>™</sup> test, aims to address the needs of individuals eligible for cancer screening. For more information, visit <u>guardanthealth.com</u> and follow the company on <u>LinkedIn</u> and <u>Twitter</u>.

------

![LOGO](g452747dsp1.jpg)

**Investor Contact:** 

Alex Kleban

<u>investors@guardanthealth.com</u> 

+1 657-254-5417

**Media Contact:** 

Michael Weist

<u>press@guardanthealth.com</u> 

+1 317-371-0035